Medtronic (MDT)
Health Care · medical devices · NYSE
Medtronic is a global healthcare technology leader dedicated to alleviating pain, restoring health, and extending life through innovative medical devices and digital solutions.
What Medtronic does
Medtronic is a global leader in medical technology, specializing in the development, manufacture, and distribution of device-based therapies for a wide range of chronic conditions. The company operates through three primary portfolios: Cardiovascular, Neuroscience, and Medical Surgical, providing solutions for heart rhythm disorders, neurological conditions, spinal issues, and advanced surgical care. Medtronic focuses on integrating biomedical engineering with data, AI, and automation to improve patient outcomes and streamline care delivery.
Themes: cardiac rhythm management, cardiovascular technology, neuroscience and neuromodulation, surgical robotics and instrumentation, digital health and remote monitoring, AI in healthcare
Fundamentals
- Price$87.75 as of 2026-10-08 close
- Market cap$112.2B as of 2026-08-28 (share count; price 2026-10-08)
- 1-year return-10.3% 2025-10-08 close $97.87 → 2026-10-08 close $87.75
- P/E23.54 as of 2026-10-08
- Net margin+13.2% FY2026, SEC XBRL
- ROE+9.7% FY2026, SEC XBRL
- Debt / equity0.57 as of 2026-09-03
- Revenue growth (YoY)+8.4% as of 2026-09-03
- Revenue CAGR (3y)+5.2% SEC XBRL
- Beta0.36 as of 2026-09-03
- Last reported earnings2026-09-01 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +3.1%; at least 14 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How MDT compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldtop 10% 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MDT is not currently in any published Top 10 list. Its scores are below.
Top 10 score
53.9 #526 of 1,379 scored · #62 of 151 in Health Care
Capital return 67th (consecutive years of dividend increases 14 years, net share count bought back over the year 0.1) and valuation 67th (price to earnings 23.5, price to book 2.2); weakest is trend (42nd, over the past 12 months this stock lagged the market by 25.3 percentage points).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2026)
Covered by reported results. In FY2026, MDT's dividend was covered by reported results (earnings payout 76%, free-cash-flow payout 67%). This describes past coverage, not a forecast.
- Earnings payout76% dividends / net income
- Free-cash-flow payout67% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2026 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Medtronic looks technically
Medtronic (MDT) is trading 1.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 11 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 17.5% below its highest point of the past year. Trading volume is running unusually high — about 6.3× its 30-day average, a sign of heightened interest.
Trend
7
| Distance from the 200-day | it is trading 1.1% below its 200-day average, the long-term trend line — a long-term downtrend | -1.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $90.05 | $90.05 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $88.69 | $88.69 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 11 trading days ago — a "golden cross", a bullish long-term signal | 11 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30) | 45.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($85.22 to $92.73) — its "stochastic" reading is 34 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 33.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 31 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $106.33 | $106.33 |
|---|---|---|
| From the 52-week high | it is 17.5% below its 52-week high (its highest price of the past year) | -17.5% |
| Above the 52-week low | it is 19.7% above its 52-week low (its lowest price of the past year) | +19.7% |
| Below the 52-week high | it is 17.5% below its highest point of the past year | 17.5% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 24 trading days ago | 24 sessions |
| All-time high | its highest closing price on record is $135.89 (set on 2021-09-09) | $135.89 |
| Given back of the 52-week move | over the past year its closes ranged ($73.75 to $105.35), and it has recovered roughly a third of its fall from last year’s high — 44% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $93.28 to $94.29. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 44.3% |
| From the all-time high | it is 35.4% below its all-time high | -35.4% |
| Nearest price level | it is trading 0.8% below a resistance level at $88.49 — a price it turned at 11 times since 2024-11-27, most recently on 2026-07-28. Since 2024-10-08 it has 5 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.8% |
| All-time low | its lowest closing price on record is $11.75 (set on 1996-07-31) | $11.75 |
| Above the all-time low | it is 646.8% above its all-time low | +646.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.20 between its high and its low — about 2.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.20 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $84.22 and $94.68 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $84.22 – $89.45 – $94.68 |
| Typical daily range (% of price) | its price moves about 2.5% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.5% |
| Stretch from the 200-day average | it is trading 0.4 daily ranges below its 200-day average price (1.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 6.3× its 30-day average, a sign of heightened interest | 6.28× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.5% |
|---|---|---|
| Gap filled | a 2.6% gap up opened on 2026-09-14 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it took 6 sessions to close | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.1 percentage points (the stock lost 5.0% while the market gained 1.0%) | -6.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 3.2 percentage points (the stock gained 7.0% while the market gained 3.8%) | +3.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 15.7 percentage points (the stock gained 1.7% while the market gained 17.5%) | -15.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 25.3 percentage points (the stock lost 10.3% while the market gained 15.0%) | -25.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 5.0% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is sitting right on the average price paid so far this year, so the typical buyer over that stretch is roughly break-even. That average is $87.58 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +0.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-09-01 (its 8-K), so the typical buyer over that stretch is under water. That average is $88.55 — a volume-weighted average of daily closes over 27 sessions, not a true tick-by-tick VWAP. | -0.9% |
Price levels it has turned at before
MDT last closed at $87.75 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $88.49 | Resistance | 0.8% above the last close | turned there 11 times · 2024-11-27 to 2026-07-28 |
| $85.21 | Support | 2.9% below the last close | turned there 8 times · 2025-02-18 to 2026-10-01 |
| $90.49 | Resistance | 3.1% above the last close | turned there four times · 2025-03-12 to 2026-09-11 |
| $83.19 | Support | 5.2% below the last close | turned there twice · 2024-11-20 to 2026-06-04 |
| $92.52 | Resistance | 5.4% above the last close | turned there 7 times · 2024-10-24 to 2025-10-01 |
| $81.52 | Support | 7.1% below the last close | turned there twice · 2025-04-21 to 2025-05-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Unusually heavy trading volume · Broke down to a new 20-day low · lagging the market · Trading at this year’s average price paid (anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.75 mean, 1=Strong Buy…5=Strong Sell) — 24 analysts
- Mean price target$104.83 range $85.00 – $121.00; median $106.00
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MDT
- Consensus EPS estimate$1.33 next reporting period, as of 2026-10-03
- Readings revised upward0% of 4 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Intense competition and pricing pressure in the medical device market.","Regulatory hurdles for new product approvals and compliance with healthcare laws.","Reliance on complex global supply chains and manufacturing operations."]
What changed in the latest 10-Q
AI-assisted comparison of MDT's 10-Q filed 2026-02-24 against the prior one filed 2025-11-25.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing (2026-02-24): Reference to 'three and nine months ended January 23, 2026' instead of 'three and six months ended October 24, 2025'
- In newer filing (2026-02-24): Addition of 'Certain litigation charges, net' line item in three months ended January 23, 2026 reconciliation ($62 million income before taxes)
- In newer filing (2026-02-24): Three months ended January 23, 2026 includes $30 million accelerated amortization footnote (1) compared to $46 million in prior period
- In newer filing (2026-02-24): Three months ended January 23, 2026 footnote (3) explicitly references 'costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System'
- In newer filing (2026-02-24): Three months ended January 24, 2025 comparative period includes 'Medical device regulations' adjustment line item
- In newer filing (2026-02-24): Nine months ended January 23, 2026 reconciliation includes 'Other' adjustment line item ($39 million)
- Removed:
- In older filing (2025-11-25): 'Computed based on the amounts in thousands' language removed and replaced with 'computed based on the actual amounts'
- In older filing (2025-11-25): Three months ended October 24, 2025 does not separately present 'Certain litigation charges, net' line
- In older filing (2025-11-25): Three months ended October 25, 2024 includes specific 'Certain tax adjustments, net' description footnote (5) that is not replicated in newer filing's comparative period presentation
- Reworded:
- Older filing states amounts 'computed based on the amounts in thousands,' newer filing states 'computed based on the actual amounts'
- Older filing footnote (2) for October 24, 2025 period states charges relate to 'employee termination benefits and facility related and contract termination costs'; newer filing expands to include 'and asset write offs'
- Older filing footnote (3) for October 24, 2025 combines Diabetes separation and HVAD System costs in single explanation; newer filing separates Diabetes charges from HVAD System costs in footnote (3)
- Notes:
- Newer filing appears truncated at end of nine months ended January 24, 2025 reconciliation table, preventing full comparison of that period's details
- Page numbers differ (36-38 in newer vs. 32-34 in older), reflecting different document lengths
- The periods covered differ materially: newer filing covers Q3 ended January 23, 2026 (9 months ended same date), older filing covers Q1 ended October 24, 2025 (6 months ended same date), making some changes attributable to different reporting periods rather than policy changes
Risk Factors
- Added:
- In newer filing (2026-02-24), Item 2 share repurchase table covers third quarter of fiscal year 2026 with periods 10/25/2025-11/21/2025, 11/22/2025-12/26/2025, and 12/27/2025-1/23/2026, showing 917,675 total shares purchased at $92.63 average price
- In newer filing (2026-02-24), Item 5 includes Rule 10b5-1 Director and Officer Trading Arrangements disclosure stating none of directors or officers adopted or terminated such arrangements during quarter ended January 23, 2026
- Removed:
- Older filing (2025-11-25) Item 2 share repurchase table for second quarter of fiscal year 2026 with periods 7/26/2025-8/22/2025, 8/23/2025-9/26/2025, and 9/27/2025-10/24/2025, showing 3,300,161 total shares purchased at $93.54 average price is not present in newer filing
- Older filing (2025-11-25) Item 5 Exchange Act Section 3(r) Disclosure regarding Medtronic's engagement with Russia's Federal Security Service is not present in newer filing
- Reworded:
- Currency exchange rate derivative instruments outstanding date changed from October 24, 2025 ($20.6 billion) in older filing to January 23, 2026 ($19.9 billion) in newer filing
- Net unrealized gain position on currency contracts changed from $100 million at October 24, 2025 (older) to $142 million at January 23, 2026 (newer)
- Interest rate sensitivity change from $86 million (October 24, 2025) in older filing to $89 million (January 23, 2026) in newer filing for 50 basis point change impact
- Reference to Note 8 changed from 'Note 8 to' in older filing to 'Note 8 in' in newer filing regarding consolidated financial statements
- Reference to Note 16 changed from 'Note 16 to' in older filing to 'Note 16 in' in newer filing regarding consolidated financial statements
- Notes:
- Page numbers differ between filings (57-60 in newer vs 52-53 in older), reflecting different document lengths
- The removals represent standard quarterly updates reflecting different reporting periods, not substantive deletions of policy or disclosure frameworks
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 1 sell ($138883) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 1 sell ($138883) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 4 sells ($733780) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-16. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MDT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 18 matched disclosures for MDT from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Short interest (FINRA)
MDT had 17,229,743 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
MDT had 1.35% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.97 days to cover at the same settlement.
- Reported short interest (shares) 17,229,743
- Short interest (% of shares outstanding) 1.35%
- Prior settlement (shares) 12,134,511
- Reported change 41.99%
- Days to cover (reported) 1.97
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Boston Scientific (BSX)
- Abbott Laboratories (ABT)
- Edwards Lifesciences (EW)
- Stryker (SYK)
- Johnson & Johnson MedTech (JNJ)
- Zimmer Biomet (ZBH)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MDT vs…
Medtronic is found in…
Frequently asked questions
What does Medtronic (MDT) do?
Medtronic is a global leader in medical technology, specializing in the development, manufacture, and distribution of device-based therapies for a wide range of chronic conditions. The company operates through three primary portfolios: Cardiovascular, Neuroscience, and Medical Surgical, providing solutions for heart rhythm disorders, neurological conditions, spinal issues, and advanced surgical care.
What sector is Medtronic (MDT) in?
Medtronic (MDT) is classified in the Health Care sector. Its industry is medical devices. It trades on NYSE.
Does MDT pay a dividend?
Yes — Medtronic (MDT) pays a dividend, with an indicated yield of about 3.13% and at least 14 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Medtronic's (MDT) competitors?
Notable peers of Medtronic (MDT) include Boston Scientific, Abbott Laboratories, Edwards Lifesciences, Stryker and Johnson & Johnson MedTech. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in MDT?
Yes — we hold 18 matched STOCK Act disclosures for MDT from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Medtronic (MDT) overbought or oversold right now?
Medtronic (MDT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 46, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MDT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.